Ceritinib in ALK-rearranged non-small-cell lung cancer

Shaw, Alice T; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel SW; Felip, Enriqueta; Chow, Laura QM; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Juergen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Santoro, Armando; Lau, Yvonne Y; Goldwasser, Meredith; Boral, Anthony L; Engelman, Jeffrey A

doi:10.1056/NEJMoa1311107

Ceritinib in ALK-rearranged non-small-cell lung cancer

Author:

Shaw, Alice T

Kim, Dong-Wan ; Mehra, Ranee ; Tan, Daniel SW ; Felip, Enriqueta ; Chow, Laura QM ; Camidge, D Ross ; Vansteenkiste, Johan ; Sharma, Sunil ; De Pas, Tommaso ; Riely, Gregory J ; Solomon, Benjamin J ; Wolf, Juergen ; Thomas, Michael ; Schuler, Martin ; Liu, Geoffrey ; Santoro, Armando ; Lau, Yvonne Y ; Goldwasser, Meredith ; Boral, Anthony L ; Engelman, Jeffrey A

Keywords:

Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Middle Aged, Protein Kinase Inhibitors, Pyrimidines, Receptor Protein-Tyrosine Kinases, Recombination, Genetic, Sulfones, Treatment Outcome, Young Adult, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, EML4-ALK FUSION GENE, KINASE INHIBITOR, ACQUIRED-RESISTANCE, CLINICAL RESISTANCE, MUTATION, EGFR, CRIZOTINIB, STI-571, Anaplastic Lymphoma Kinase, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies.